IL310241A - Lupus treatment - Google Patents

Lupus treatment

Info

Publication number
IL310241A
IL310241A IL310241A IL31024124A IL310241A IL 310241 A IL310241 A IL 310241A IL 310241 A IL310241 A IL 310241A IL 31024124 A IL31024124 A IL 31024124A IL 310241 A IL310241 A IL 310241A
Authority
IL
Israel
Prior art keywords
lupus
treatment
Prior art date
Application number
IL310241A
Other languages
English (en)
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL310241A publication Critical patent/IL310241A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL310241A 2021-07-27 2022-07-26 Lupus treatment IL310241A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163225974P 2021-07-27 2021-07-27
US202163254663P 2021-10-12 2021-10-12
PCT/EP2022/070860 WO2023006700A1 (en) 2021-07-27 2022-07-26 Treatment of lupus

Publications (1)

Publication Number Publication Date
IL310241A true IL310241A (en) 2024-03-01

Family

ID=83059135

Family Applications (1)

Application Number Title Priority Date Filing Date
IL310241A IL310241A (en) 2021-07-27 2022-07-26 Lupus treatment

Country Status (9)

Country Link
US (1) US20250326850A1 (https=)
EP (1) EP4377349A1 (https=)
JP (1) JP2024527001A (https=)
KR (1) KR20240038773A (https=)
AU (1) AU2022317215A1 (https=)
CA (1) CA3226744A1 (https=)
IL (1) IL310241A (https=)
TW (1) TW202340245A (https=)
WO (1) WO2023006700A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD1120170S1 (en) * 2024-03-28 2026-03-24 Karsten Manufacturing Corporation Golf club head

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
KR101225299B1 (ko) 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
US7662381B2 (en) 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
KR20160070165A (ko) 2008-02-08 2016-06-17 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
CA2772921A1 (en) 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途

Also Published As

Publication number Publication date
AU2022317215A1 (en) 2024-02-29
WO2023006700A1 (en) 2023-02-02
JP2024527001A (ja) 2024-07-19
US20250326850A1 (en) 2025-10-23
TW202340245A (zh) 2023-10-16
EP4377349A1 (en) 2024-06-05
CA3226744A1 (en) 2023-02-02
KR20240038773A (ko) 2024-03-25

Similar Documents

Publication Publication Date Title
GB201804514D0 (en) Treatment of pyroptosis
IL315503A (en) Treatment methods
GB202103774D0 (en) Detectiion of Ransomware
IL320711A (en) Treatment methods
IL290983A (en) Treatment methods
GB201804515D0 (en) Treatment of necroptosis
IL288011A (en) Treatment of cutaneous lupus erythematosus
SI4125911T1 (sl) Obicetrapib za zdravljenje demence
IL287250A (en) treatment method
GB201907305D0 (en) Treatment of conditions
IL310241A (en) Lupus treatment
GB202201824D0 (en) Methods of treatment
GB201918853D0 (en) Methods of treatment
GB202102257D0 (en) Treatment of shells
GB202201825D0 (en) Methods of treatment
GB202201819D0 (en) Methods of treatment
HK40115317A (en) Treatment of lupus
HK40113692A (en) Treatment of lupus
GB201911056D0 (en) Treatment of ADD/ADHD
GB202101251D0 (en) Treatment of conditions
GB202118011D0 (en) Methods of treatment
GB202118007D0 (en) Methods of treatment
GB202118006D0 (en) Methods of treatment
GB202108245D0 (en) Methods of treatment
GB202108242D0 (en) Methods of treatment